HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rodan + Fields Prostaglandin Lash Boost Suit Appears Headed For Settlement

Executive Summary

The San Francisco-based multi-level beauty marketer seems intent on putting an end to a multi-year, consolidated putative class action in California federal court alleging it failed to disclose risks associated with the prostaglandin analog in its Lash Boost conditioning serum.

You may also be interested in...

Shiseido Skin Care For Gen-Z Men; e.l.f. Cosmetics For Gamers; Summer Beauty Launches In Brief

L’Oreal Paris delivers permanent hair color designed specifically for men, Shiseido targets new skin care to Gen-Z males, and e.l.f. Beauty continues to play nice with gamers, launching a limited-edition Game Up cosmetics range. More product launch news in brief.

Prostaglandin Analogues In Eyelash Cosmetics: Rodan & Fields To Settle Litigation For $38M

R&F will establish funds totaling $38m to put the kibosh on claims of fraud and unfair competition in US federal and state class actions, while maintaining it never intended its prostaglandin analogue-containing Lash Boost to impart drug-like structure and/or function effects on the human body. The settlement does not require R&F to stop selling Lash Boost or reformulate the product.

CIR Panel Throws Up Hands At Airbrush Ingredient Safety, Defers To FDA On Eyelash ‘Enhancers’

The US-based Cosmetic Ingredient Review’s independent experts finalized four ingredient safety reports at its 7-8 March meeting, advanced nine tentative assessments, and issued two insufficient data announcements. The panel continues to face challenges in assessing ingredients used in airbrush applications and decided against prioritizing review of eyelash-"enhancing" prostaglandin analogues.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts